Abeona closes sale of Rare Pediatric Disease PRV for $155M; cash at $225M

ABEONA THERAPEUTICS INC.

Closed sale of Rare Pediatric Disease Priority Review Voucher for $155M gross proceeds on June 27, 2025.
Unrestricted cash, equivalents, and short-term investments totaled approximately $225M as of June 30, 2025.
CFO expects over two years of operating capital without further capital infusion; profitability projected early 2026.
First ZEVASKYN patient treatment anticipated in Q3 2025.

item 2.01item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.